Yahoo! Finance Search - Finance Home - Yahoo! - Help

Friday, February 5 2016 5:05pm ET - U.S. Markets Closed.
Industry Center - Drug Manufacturers - Major
Industry Center > Drug Manufacturers - Major > News
More On This Industry
· Summary
News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Biotechnology
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
· REIT - Retail
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
 
Drug Manufacturers - Major News
Latest News
Friday, Feb 5, 2016
·SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in GW Pharmaceuticals plc of Class Action Lawsuit and Upcoming Deadline – GWPH
GlobeNewswire - 34 minutes ago
·Call Martin Shkreli Whatever You Want, But Not A Pharma CEO
at Forbes.com - 52 minutes ago
·Gilead Sciences 2016 Guidance: Sandbagging Wall Street Again?
at Motley Fool - 1 hour, 25 minutes ago
·Valeant's Share Price Continues to Decline
- 1 hour, 54 minutes ago
·[$$] J&J, AbbVie Shares Drop on Potential Drug Competition
at The Wall Street Journal Online - Fri 1:22 pm ET
·A Checkup On A Big Healthcare ETF
- Fri 1:19 pm ET
·U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
Business Wire - Fri 12:47 pm ET
·FDA staff supports Celltrion's biosimilar Remicade
Reuters - Fri 9:27 am ET
·Why Isn’t Johnson & Johnson Making More Acquisitions?
at Motley Fool - Fri 9:01 am ET
·Biostar Pharmaceuticals to Effect Reverse Stock Split
PR Newswire - Fri 9:00 am ET
·Celltrion’s Copy of J&J’s Remicade Gets FDA Staff Support
at Bloomberg - Fri 8:02 am ET
·FDA reviewers support Celltrion's biosimilar Remicade
Reuters - Fri 7:56 am ET
·​Affinivax proves you can launch a biotech without the help of VCs
at bizjournals.com - Fri 7:06 am ET
·Pfizer's Pipeline Productivity Is Improving
Morningstar.com - Fri 7:00 am ET
·Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed
PR Newswire - Fri 2:19 am ET
Thursday, Feb 4, 2016
·2 Numbers in Merck's 4th-Quarter Report That Have Investors Worried
at Motley Fool - Thu 6:16 pm ET
·4 Can't-Miss Numbers From GlaxoSmithKline's Fourth-Quarter Results
at Motley Fool - Thu 4:49 pm ET
·Moody's Affirms Six Classes of COMM 2015-LC19
- Thu 4:26 pm ET
·Novo Nordisk A/S Taps the Growth Brakes
at Motley Fool - Thu 4:15 pm ET
·Is Inovio Pharmaceuticals' Zika Surge Premature?
at Motley Fool - Thu 3:59 pm ET
More Latest News...
  

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Drug Manufacturers - Major Headlines
More Finance RSS Feeds


Copyright © 2016 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2016 Morningstar, Inc. All Rights Reserved. Company information © 2016 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2016, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?